Iowa State Bank Sells 531 Shares of Gilead Sciences, Inc. $GILD

Iowa State Bank lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 24,480 shares of the biopharmaceutical company’s stock after selling 531 shares during the period. Iowa State Bank’s holdings in Gilead Sciences were worth $2,714,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of GILD. Ariel Investments LLC boosted its holdings in shares of Gilead Sciences by 7.7% in the first quarter. Ariel Investments LLC now owns 430,424 shares of the biopharmaceutical company’s stock worth $48,229,000 after buying an additional 30,630 shares during the last quarter. One Wealth Advisors LLC increased its stake in shares of Gilead Sciences by 34.8% in the second quarter. One Wealth Advisors LLC now owns 9,163 shares of the biopharmaceutical company’s stock worth $1,016,000 after purchasing an additional 2,364 shares in the last quarter. Golden State Wealth Management LLC raised its position in shares of Gilead Sciences by 14.5% during the 1st quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company’s stock valued at $97,000 after purchasing an additional 109 shares during the period. Swedbank AB lifted its stake in shares of Gilead Sciences by 0.8% during the 1st quarter. Swedbank AB now owns 2,118,632 shares of the biopharmaceutical company’s stock valued at $237,393,000 after buying an additional 16,663 shares in the last quarter. Finally, Covea Finance boosted its holdings in Gilead Sciences by 69.5% in the 2nd quarter. Covea Finance now owns 51,700 shares of the biopharmaceutical company’s stock worth $5,732,000 after buying an additional 21,200 shares during the period. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Stock Performance

Shares of GILD opened at $112.69 on Monday. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a 52-week low of $83.98 and a 52-week high of $121.83. The company has a 50-day simple moving average of $114.34 and a 200-day simple moving average of $109.97. The company has a market capitalization of $139.83 billion, a PE ratio of 22.45, a P/E/G ratio of 0.77 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company had revenue of $7.08 billion during the quarter, compared to analysts’ expectations of $6.95 billion. During the same period last year, the company posted $2.01 earnings per share. The firm’s quarterly revenue was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Equities research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.8%. The ex-dividend date was Monday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is 62.95%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction on Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $283,925.00. Following the completion of the transaction, the chief financial officer directly owned 159,555 shares in the company, valued at approximately $18,120,661.35. The trade was a 1.54% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $113.94, for a total transaction of $1,139,400.00. Following the transaction, the chief executive officer directly owned 605,725 shares in the company, valued at approximately $69,016,306.50. This represents a 1.62% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 82,000 shares of company stock worth $9,402,130. 0.27% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Dbs Bank upgraded Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a research report on Saturday, September 27th. Rothschild & Co Redburn raised their price target on Gilead Sciences from $136.00 to $143.00 and gave the stock a “buy” rating in a research note on Friday, September 12th. UBS Group lifted their price objective on Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a report on Friday, August 8th. Finally, JPMorgan Chase & Co. boosted their price target on Gilead Sciences from $135.00 to $145.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 16th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $117.17.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.